Pilot study to assess the safety and efficacy of switching the NNRTI or PI to maraviroc in HIV-1-infected subjects with persistent viremia suppression experiencing NNRTI or PI-related dyslipidemia [ENSAYO CLiNICO PILOTO PARA EVALUAR LA SEGURIDAD Y EFICACIA DE CAMBIAR EL ITINAN O EL IP A MARAVIROC EN PACIENTES INFECTADOS POR EL VIH-1 CON CARGA VIRAL INDETECTABLE Y DISLIPEMIA ASOCIADA A LOS ANTIRETROVIRALES]

Trial Profile

Pilot study to assess the safety and efficacy of switching the NNRTI or PI to maraviroc in HIV-1-infected subjects with persistent viremia suppression experiencing NNRTI or PI-related dyslipidemia [ENSAYO CLiNICO PILOTO PARA EVALUAR LA SEGURIDAD Y EFICACIA DE CAMBIAR EL ITINAN O EL IP A MARAVIROC EN PACIENTES INFECTADOS POR EL VIH-1 CON CARGA VIRAL INDETECTABLE Y DISLIPEMIA ASOCIADA A LOS ANTIRETROVIRALES]

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Sep 2012

At a glance

  • Drugs Maraviroc (Primary) ; Antiretrovirals; Atazanavir; Atazanavir/ritonavir; Darunavir/ritonavir; Efavirenz; Fosamprenavir; Lopinavir/ritonavir; Nevirapine; Ritonavir; Tipranavir
  • Indications HIV infections
  • Focus Therapeutic Use
  • Acronyms MARAVI-SWITCH
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 08 Sep 2012 Status changed from recruiting to completed as reported by European Clinical Trials Database.
    • 16 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top